Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01629823 · ClinicalTrials.gov registry record · NA
Effect of Positive Airway Pressure on Reducing Airway Reactivity in Patients With Asthma (CPAP)
A NA study, sponsored by American Lung Association Asthma Clinical Research Centers.
- Completed
- Registry status
- NA
- Development phase
- 209
- Enrollment target
NCT01629823: Completed NA study, sponsored by American Lung Association Asthma Clinical Research Centers.
NCT01629823 is a NA study that has completed, run by American Lung Association Asthma Clinical Research Centers. The registered enrollment target is 209 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01629823, a NA study, has completed, sponsored by American Lung Association Asthma Clinical Research Centers.
- COMPLETED
- Registry status
- NA
- Development phase
- 209 participants
- Enrollment target
Study Summary
The CPAP trial is a 3-arm parallel design randomized sham-controlled trial. Participants are randomly assigned in equal allocation to one of three treatments: CPAP 10 cm water (H₂O) (high) vs. CPAP 5 cm H₂O (medium) vs. CPAP Sham (less than 1 cm H₂O, Low). The treatment period is 12 weeks with airways reactivity assessed at baseline, 6 and 12 weeks of treatment and after a 2 week washout.
Primary Outcome
The primary outcome measure was the change in provocative concentration of methacholine causing a 20% fall in forced expiratory volume in 1 second (FEV₁) (PC20) from baseline to 12 weeks. Modified American Thoracic Society guidelines were followed for pre-bronchodilator spirometry and methacholine challenge testing using the 5 breath dosimeter technique. Up to eleven doses, each a doubling concentration of methacholine (Provocholine™), were inhaled starting at 0.03 mg/mL until a 20% or greater f
Interventions
- DEVICE Continuous Positive Airway Pressure device (Resmed, Swift, Mirage)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 209 participants |
| Start Date | 2012-07 |
| Est. Completion | 2014-12 |
| Phase | NA |
What the finished NCT01629823 record still lists
NCT01629823 is an interventional study that assigns participants to a tested intervention. The registered 209 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (85% lower).
The record links to 0 conditions, and to 1 intervention - of which Continuous Positive Airway Pressure device (Resmed, Swift, Mirage) is the first listed.
NCT01629823 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01629823 about?
NCT01629823 is a clinical study titled "Effect of Positive Airway Pressure on Reducing Airway Reactivity in Patients With Asthma (CPAP)". The CPAP trial is a 3-arm parallel design randomized sham-controlled trial. Participants are randomly assigned in equal allocation to one of three treatments: CPAP 10 cm water (H₂O) (high) vs. CPAP 5 cm H₂O (medium) vs. CPAP Sham (less than 1 cm H₂O, Low). The treatment period is 12 weeks with airwa...
What is the current status of trial NCT01629823?
This trial is currently completed. It is a NA study. The enrollment target is 209 participants. The study started on 2012-07. Estimated completion is 2014-12.
What interventions are being tested in trial NCT01629823?
The interventions under investigation include: Continuous Positive Airway Pressure device (Resmed, Swift, Mirage) (DEVICE).
Who is sponsoring clinical trial NCT01629823?
This trial is sponsored by American Lung Association Asthma Clinical Research Centers, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01629823's enrollment target sits among peer trials
209 496th of 2000 higher than 1,505 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04742634 · 209 participants · Phase 1
Pre-emptive Therapy With DEC-C to Improve Outcomes in MDS Patients With Measurable Residual Disease Post Allogeneic Hematopoietic Cell Transplant
- NCT07214688 · 209 participants · Phase 2
Fludarabine and Intermediate-dose TBI Followed by PTCy in Patients Undergoing Allo Transplant for Heme Malignancies
- NCT02665923 · 210 participants
Gastric Emptying in Neonates and Infants After Formula Feeding
- NCT03322891 · 210 participants · NA
Improving Health Literacy in African-American Prostate Cancer Patients
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia